We are live on ! Find out more
JBIO

Jade Biosciences
JBIO

58 hedge funds and large institutions have $386M invested in Jade Biosciences in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0.01% less ownership

Funds ownership: 2.95% → 2.94% (-0.01%)

2% less funds holding

Funds holding: 59 → 58 (-1)

21% less capital invested

Capital invested by funds: $488M → $386M (-$102M)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
58
Holders Change
-1
Holders Change %
-1.69%
% of All Funds
0.92%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
2
Increased
22
Reduced
12
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
FLSM
Frazier Life Sciences Management
California
+$3.25M
2
GPP
Great Point Partners
Connecticut
+$2.46M
3
SCM
Silverarc Capital Management
Massachusetts
+$1.55M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.17M
5
BlackRock
BlackRock
New York
+$931K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$5.01M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.07M
3
OCA
Octagon Capital Advisors
New York
-$1.92M
4
HS
HighVista Strategies
Massachusetts
-$717K
5
FAM
Fred Alger Management
New York
-$513K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$112M – – –
SI
2
Sofinnova Investments
California
$51M – – –
TCM
3
TCG Crossover Management
California
$29.9M – – –
AVLSA
4
Atlas Venture Life Science Advisors
Massachusetts
$27.7M – – –
BBA
5
Baker Bros. Advisors
New York
$26.6M – – –
CAM
6
Cormorant Asset Management
Massachusetts
$21.2M – – –
FLSM
7
Frazier Life Sciences Management
California
$16.4M +$3.25M +6,000 +21%
DCM
8
Driehaus Capital Management
Illinois
$16.1M -$100K -185 -0.5%
GPP
9
Great Point Partners
Connecticut
$14.8M +$2.46M +4,545 +17%
O
10
OrbiMed
New York
$10.3M – – –
BlackRock
11
BlackRock
New York
$9.27M +$931K +1,718 +10%
OMC
12
OUP Management Company
Pennsylvania
$8.19M – – –
Vanguard Group
13
Vanguard Group
Pennsylvania
$8.13M +$1.17M +2,158 +14%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$7.19M -$3.07M -5,659 -27%
OCA
15
Octagon Capital Advisors
New York
$6.75M -$1.92M -3,552 -20%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$3.39M +$723K +1,335 +23%
GTC
17
Ghost Tree Capital
New York
$2.73M – – –
State Street
18
State Street
Massachusetts
$2.46M -$114K -210 -4%
Northern Trust
19
Northern Trust
Illinois
$1.5M +$348K +642 +26%
SCM
20
Silverarc Capital Management
Massachusetts
$1.36M +$1.55M +2,857 New
NCM
21
Nantahala Capital Management
Connecticut
$1.29M – – –
Millennium Management
22
Millennium Management
New York
$724K +$309K +571 +60%
Skandinaviska Enskilda Banken (SEB)
23
Skandinaviska Enskilda Banken (SEB)
Sweden
$690K – – –
EP
24
Eversept Partners
New York
$682K – – –
NFGH
25
Nan Fung Group Holdings
Hong Kong
$650K – – –
1
2 3

JBIO Hedge Fund Activity: Q3 2023 in Review

58 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q3 2023, worth a combined $386M — down 21% from $488M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of JBIO and 2 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 22 added.

The largest buyer was Frazier Life Sciences Management, adding an estimated $3.25M. The largest seller was Citadel Advisors, exiting entirely with an estimated $5.01M sold.

  • 58 institutional investors held Jade Biosciences (JBIO) as of Q3 2023, down from 59 in Q2 2023.
  • Funds reported $386M of Jade Biosciences stock for Q3 2023, down 21% quarter-over-quarter.
  • 2 funds opened new Jade Biosciences positions in Q3 2023 and 3 closed out, a net change of -1 holder.
  • The largest Jade Biosciences buyer in Q3 2023 was Frazier Life Sciences Management, an estimated $3.25M added.
  • The largest Jade Biosciences seller in Q3 2023 was Citadel Advisors, an estimated $5.01M sold.

Based on aggregated 13F filings for Q3 2023.